- Mechanism of LDH and IL-8 Involved in pancreatic cancer Pain and the Correlation of Pain Degree
LDH and IL-8 in pancreatic cancer
Abstract
Objective: To observe the mechanism of lactate dehydrogenase (LDH) and interleukin 8 (IL-8) in pancreatic cancer pain and their correlation with pain degree. Methods: 126 patients with pancreatic cancer who visited our hospital from January 2021 to February 2023 were selected. The patients were divided into 58 patients with low pain (1~3 points) and 68 patients with high pain (4~10 points) by visual analog scale (VAS). And 50 health examinees in the same period were selected as the healthy control group. The serum LDH and IL-8 concentrations are analyzed by enzyme-linked immunosorbent assay, as well as the subjective pain grading method scoreis analyzed. The differences in LDH and IL-8 concentrations among the three groups of patients were compared. Pearson correlation analysis was used to investigate the correlation between LDH, IL-8 concentrations and patient pain. Binary logistic regression was used to determine independent risk factors for high pain, and ROC curves were used to analyze the diagnostic efficacy of each indicator. Result: The serum LDH and IL-8 concentrations in the high pain group were exceed the low pain group’s (P<0.05). The serum LDH and IL-8 concentrations in the low pain groupexceed the healthy control group’s(P<0.05). Pearson correlation analysis revealed a positive correlation between serum LDH concentration and pain grading (r=0.736, P=0.000). The serum IL-8 has positive correlation with pain grading (r=0.680, P=0.000). Serum LDH and IL-8 concentrations have positive correlation(r=0.589, P=0.000). LDH and IL-8 concentrations are independent risk factors for high pain levels (OR=1.033, 1.142, P<0.05). The logistic regression prediction model formula was used: Y=constant+B1X1+B2X2+...+BnXn to set the joint diagnostic prediction model as -12.063+0.033×LDH+0.133×IL-8. The areas under the ROC curves of LDH, IL-8, and predictive model (LDH+IL-8) in patients with high pain were 0.925, 0.945, and 0.974, respectively. The relevant standards for LDH are>190U/L, IL-8 is>36pg/mL, and the relevant standards for prediction models are>5.75. Conclusion: LDH and IL-8 participate in the pain aggravation process of pancreatic cancer, and are closely related to the pain grading. The combination of LDH and IL-8 can be used as a biological indicator to evaluate the pain severity of pancreatic cancer, and provide reference for clinical diagnosis and treatment.
References
[1] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021. 71(1): 7-33.
[2] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021. 71(3): 209-249.
[3] Zhao C, Gao F, Li Q, Liu Q, Lin X. The Distributional Characteristic and Growing Trend of Pancreatic Cancer in China. Pancreas. 2019. 48(3): 309-314.
[4] Wang C, Lin T, Chen X, et al. The association between pain and WHO grade of pancreatic neuroendocrine neoplasms: A multicenter study. Cancer Biomark. 2023. 36(4): 279-286.
[5] Li X, Shi H, Zhang D, et al. Paeonol alleviates neuropathic pain by modulating microglial M1 and M2 polarization via the RhoA/p38MAPK signaling pathway. CNS Neurosci Ther. 2023 .
[6] Wu C, Huang X, Li M, Wang Z, Zhang Y, Tian B. Crosstalk between circRNAs and the PI3K/AKT and/or MEK/ERK signaling pathways in digestive tract malignancy progression. Future Oncol. 2022. 18(40): 4525-4538.
[7] Wang H, Wang J, Wang J, Cui W, Sun M, Liu Y. Relationships of pain in pancreatic cancer patients with pathological stage and expressions of NF-κB and COX-2. J BUON. 2020. 25(1): 448-453.
[8] Qiu X, Shi Z, Tong F, et al. Biomarkers for predicting tumor response to PD-1 inhibitors in patients with advanced pancreatic cancer. Hum Vaccin Immunother. 2023. 19(1): 2178791.
[9] Wyse JM, Sahai AV. EUS-guided celiac plexus neurolysis for pancreas cancer - Finally established or still under review. Best Pract Res Clin Gastroenterol. 2022. 60-61: 101809.
[10] Han CQ, Tang XL, Zhang Q, Nie C, Liu J, Ding Z. Predictors of pain response after endoscopic ultrasound-guided celiac plexus neurolysis for abdominal pain caused by pancreatic malignancy. World J Gastroenterol. 2021. 27(1): 69-79.
[11] Al-Obaidi M, Kosmicki S, Harmon C, et al. Pain among older adults with gastrointestinal malignancies- results from the cancer and aging resilience evaluation (CARE) Registry. Support Care Cancer. 2022. 30(12): 9793-9801.
[12] Aitken GL, Motta M, Samuels S, Reynolds PT, Gannon CJ, Llaguna OH. Impact of Palliative Interventions on Survival of Patients with Unresected Pancreatic Cancer: Review of the 2010-2016 National Cancer Database. Am J Hosp Palliat Care. 2023 : 10499091231174620.
[13] Filippiadis D, Ptohis N, Efthymiou E, Kelekis A. A Technical Report on the Performance of Percutaneous Cryoneurolysis of Splanchnic Nerves for the Treatment of Refractory Abdominal Pain in Patients with Pancreatic Cancer: Initial Experience. Cardiovasc Intervent Radiol. 2021. 44(5): 789-794.
[14] Zheng G, Ren J, Shang L, Bao Y. Sonic Hedgehog Signaling Pathway: A Role in Pain Processing. Neurochem Res. 2023. 48(6): 1611-1630.
[15] Ozcan S, Akın S, Yıldız Altun A, Bolat E, Önal SA. [Effective pain therapy can improve the survival of patients with pancreatic cancer]. Agri. 2019. 31(3): 145-149.
[16] Spaziani E, Di Filippo AR, Caruso G, et al. An uncommon clinical presentation of primary pancreatic lymphoma: Bleeding. Case report and literature review. Ann Ital Chir. 2021. 10.
[17] Saif MW. Primary pancreatic lymphomas. JOP. 2006. 7(3): 262-73.
[18] Ji F, Fu SJ, Guo ZY, et al. Prognostic value of combined preoperative lactate dehydrogenase and alkaline phosphatase levels in patients with resectable pancreatic ductal adenocarcinoma. Medicine (Baltimore). 2016. 95(27): e4065.
[19] Komar HM, Hart PA, Cruz-Monserrate Z, Conwell DL, Lesinski GB. Local and Systemic Expression of Immunomodulatory Factors in Chronic Pancreatitis. Pancreas. 2017. 46(8): 986-993.
[20] Reyes-Gibby CC, Shete S, Yennurajalingam S, et al. Genetic and nongenetic covariates of pain severity in patients with adenocarcinoma of the pancreas: assessing the influence of cytokine genes. J Pain Symptom Manage. 2009. 38(6): 894-902.
[21] Petrusel L, Ilies M, Leucuta D, et al. Serum JAK/STAT profile is related to the IL expression but not with the outcome in pancreatic adenocarcinoma patients. Cell Mol Biol (Noisy-le-grand). 2021. 67(3): 107-112.
[22] Noh KW, Pungpapong S, Wallace MB, Woodward TA, Raimondo M. Do cytokine concentrations in pancreatic juice predict the presence of pancreatic diseases. Clin Gastroenterol Hepatol. 2006. 4(6): 782-9.
[23] Facchinelli D, Sina S, Boninsegna E, et al. Primary pancreatic lymphoma: Clinical presentation, diagnosis, treatment, and outcome. Eur J Haematol. 2020. 105(4): 468-475.
Copyright (c) 2024 Xiaoqing Xu
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.